# A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

> **NCT07190196** · PHASE3 · RECRUITING · sponsor: **Sanofi** · enrollment: 124 (estimated)

## Conditions studied

- Immunoglobulin G4 Related Disease

## Interventions

- **DRUG:** Rilzabrutinib
- **DRUG:** Placebo
- **DRUG:** Glucocorticoid

## Key facts

- **NCT ID:** NCT07190196
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-26
- **Primary completion:** 2028-06-28
- **Final completion:** 2030-12-25
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07190196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07190196, "A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07190196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*